Russia's Sputnik Light vaccine approved for use in Palestine
Russia’s single-dose Sputnik Light vaccine against COVID-19 has been approved for use in the Palestinian territories, Russia’s RDIF sovereign wealth fund said on Monday.
The RDIF fund is marketing the Russian vaccine abroad. Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V. Sputnik Light demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered.
"Using the single-dose Sputnik Light vaccine significantly reduces the possibility of severe cases leading to hospitalization. Thanks to Sputnik Light authorities in Palestine will be able to immunize large groups in a shorter time achieving herd immunity faster," CEO of the Russian Direct Investment Fund Kirill Dmitriev said.